AAPL346.04+2.05 (+0.60%) ▲|ABBV284.56-0.24 (-0.09%) ▼|ABT102.44+1.93 (+1.92%) ▲|ACN251.79+11.53 (+4.80%) ▲|ADBE269.35+14.29 (+5.60%) ▲|AMAT379.67-29.27 (-7.16%) ▼|AMD510.23-42.50 (-7.69%) ▼|AMGN448.43+10.09 (+2.30%) ▲|AMT180.83+3.19 (+1.80%) ▲|AMZN250.25-12.13 (-4.62%) ▼|AVGO324.69-13.11 (-3.88%) ▼|AXP324.15+0.54 (+0.17%) ▲|BA188.42-3.86 (-2.01%) ▼|BAC50.92+0.14 (+0.28%) ▲|BKNG161.73+3.35 (+2.12%) ▲|BLK1,140.28-9.32 (-0.81%) ▼|BMY63.40+2.28 (+3.73%) ▲|BNY144.39-1.47 (-1.00%) ▼|BRK-B549.50+10.51 (+1.95%) ▲|C122.00-1.85 (-1.49%) ▼|CAT700.46-39.75 (-5.37%) ▼|CL97.26+3.86 (+4.13%) ▲|CMCSA22.72+0.64 (+2.91%) ▲|COF203.62-3.05 (-1.47%) ▼|COP146.03+0.36 (+0.25%) ▲|COST1,013.81+15.50 (+1.55%) ▲|CRM249.84+8.06 (+3.33%) ▲|CSCO104.94-2.33 (-2.17%) ▼|CVS94.12+1.34 (+1.44%) ▲|CVX226.22-0.57 (-0.25%) ▼|DE639.41+2.87 (+0.45%) ▲|DHR229.92-3.94 (-1.69%) ▼|DIS112.61+0.78 (+0.70%) ▲|DUK124.83+4.16 (+3.45%) ▲|EMR158.07-5.04 (-3.09%) ▼|FDX302.92+4.69 (+1.57%) ▲|GD348.39+3.68 (+1.07%) ▲|GE290.18-5.70 (-1.93%) ▼|GEV822.47-103.45 (-11.17%) ▼|GILD156.80+3.23 (+2.10%) ▲|GM76.72+0.61 (+0.79%) ▲|GOOG320.83-10.12 (-3.06%) ▼|GOOGL324.44-10.33 (-3.08%) ▼|GS887.73-16.99 (-1.88%) ▼|HD325.72+11.58 (+3.69%) ▲|HON215.32+0.59 (+0.27%) ▲|IBM249.87-1.59 (-0.63%) ▼|INTC86.11-6.85 (-7.37%) ▼|INTU353.97+18.36 (+5.47%) ▲|ISRG441.26+13.14 (+3.07%) ▲|JNJ268.91+11.13 (+4.32%) ▲|JPM334.80-0.39 (-0.12%) ▼|KO94.84+2.16 (+2.33%) ▲|LIN509.77+9.20 (+1.84%) ▲|LLY1,311.52+40.77 (+3.21%) ▲|LMT585.45+33.94 (+6.15%) ▲|LOW203.10+6.54 (+3.33%) ▲|LRCX231.69-29.12 (-11.17%) ▼|MA631.79+9.17 (+1.47%) ▲|MCD251.63+5.38 (+2.18%) ▲|MDLZ64.91+2.17 (+3.45%) ▲|MDT95.58+2.55 (+2.74%) ▲|META645.44-52.08 (-7.47%) ▼|MMM174.08-0.66 (-0.38%) ▼|MO75.86+2.03 (+2.74%) ▲|MRK147.96-1.92 (-1.28%) ▼|MS183.29-3.73 (-1.99%) ▼|MSFT523.97-8.98 (-1.69%) ▼|MU860.14-53.53 (-5.86%) ▼|NEE81.39+3.11 (+3.97%) ▲|NFLX67.22+2.18 (+3.35%) ▲|NKE38.27+0.74 (+1.96%) ▲|NOW156.69+3.57 (+2.33%) ▲|NVDA212.50-9.47 (-4.27%) ▼|ORCL123.41-5.72 (-4.43%) ▼|PEP138.27+3.57 (+2.65%) ▲|PFE30.25+0.40 (+1.34%) ▲|PG166.12+9.28 (+5.92%) ▲|PLTR197.07-4.65 (-2.31%) ▼|PM200.87+3.41 (+1.73%) ▲|QCOM172.75-5.22 (-2.93%) ▼|RTX192.53+0.93 (+0.49%) ▲|SBUX101.62+2.54 (+2.56%) ▲|SCHW92.21+0.57 (+0.62%) ▲|SO93.28+2.89 (+3.20%) ▲|SPG211.18+5.63 (+2.74%) ▲|T22.68+0.77 (+3.49%) ▲|TMO676.83-17.19 (-2.48%) ▼|TMUS158.27+4.52 (+2.94%) ▲|TSLA377.95-8.53 (-2.21%) ▼|TXN283.23-1.42 (-0.50%) ▼|UBER68.21+0.59 (+0.87%) ▲|UNH424.60+7.60 (+1.82%) ▲|UNP296.04+8.17 (+2.84%) ▲|UPS101.69+2.12 (+2.12%) ▲|USB59.91+0.86 (+1.45%) ▲|V413.95+6.10 (+1.50%) ▲|VZ44.80+1.24 (+2.84%) ▲|WFC83.02+0.60 (+0.73%) ▲|WMT120.45+2.65 (+2.25%) ▲|XOM177.34-0.75 (-0.42%) ▼|AAPL346.04+2.05 (+0.60%) ▲|ABBV284.56-0.24 (-0.09%) ▼|ABT102.44+1.93 (+1.92%) ▲|ACN251.79+11.53 (+4.80%) ▲|ADBE269.35+14.29 (+5.60%) ▲|AMAT379.67-29.27 (-7.16%) ▼|AMD510.23-42.50 (-7.69%) ▼|AMGN448.43+10.09 (+2.30%) ▲|AMT180.83+3.19 (+1.80%) ▲|AMZN250.25-12.13 (-4.62%) ▼|AVGO324.69-13.11 (-3.88%) ▼|AXP324.15+0.54 (+0.17%) ▲|BA188.42-3.86 (-2.01%) ▼|BAC50.92+0.14 (+0.28%) ▲|BKNG161.73+3.35 (+2.12%) ▲|BLK1,140.28-9.32 (-0.81%) ▼|BMY63.40+2.28 (+3.73%) ▲|BNY144.39-1.47 (-1.00%) ▼|BRK-B549.50+10.51 (+1.95%) ▲|C122.00-1.85 (-1.49%) ▼|CAT700.46-39.75 (-5.37%) ▼|CL97.26+3.86 (+4.13%) ▲|CMCSA22.72+0.64 (+2.91%) ▲|COF203.62-3.05 (-1.47%) ▼|COP146.03+0.36 (+0.25%) ▲|COST1,013.81+15.50 (+1.55%) ▲|CRM249.84+8.06 (+3.33%) ▲|CSCO104.94-2.33 (-2.17%) ▼|CVS94.12+1.34 (+1.44%) ▲|CVX226.22-0.57 (-0.25%) ▼|DE639.41+2.87 (+0.45%) ▲|DHR229.92-3.94 (-1.69%) ▼|DIS112.61+0.78 (+0.70%) ▲|DUK124.83+4.16 (+3.45%) ▲|EMR158.07-5.04 (-3.09%) ▼|FDX302.92+4.69 (+1.57%) ▲|GD348.39+3.68 (+1.07%) ▲|GE290.18-5.70 (-1.93%) ▼|GEV822.47-103.45 (-11.17%) ▼|GILD156.80+3.23 (+2.10%) ▲|GM76.72+0.61 (+0.79%) ▲|GOOG320.83-10.12 (-3.06%) ▼|GOOGL324.44-10.33 (-3.08%) ▼|GS887.73-16.99 (-1.88%) ▼|HD325.72+11.58 (+3.69%) ▲|HON215.32+0.59 (+0.27%) ▲|IBM249.87-1.59 (-0.63%) ▼|INTC86.11-6.85 (-7.37%) ▼|INTU353.97+18.36 (+5.47%) ▲|ISRG441.26+13.14 (+3.07%) ▲|JNJ268.91+11.13 (+4.32%) ▲|JPM334.80-0.39 (-0.12%) ▼|KO94.84+2.16 (+2.33%) ▲|LIN509.77+9.20 (+1.84%) ▲|LLY1,311.52+40.77 (+3.21%) ▲|LMT585.45+33.94 (+6.15%) ▲|LOW203.10+6.54 (+3.33%) ▲|LRCX231.69-29.12 (-11.17%) ▼|MA631.79+9.17 (+1.47%) ▲|MCD251.63+5.38 (+2.18%) ▲|MDLZ64.91+2.17 (+3.45%) ▲|MDT95.58+2.55 (+2.74%) ▲|META645.44-52.08 (-7.47%) ▼|MMM174.08-0.66 (-0.38%) ▼|MO75.86+2.03 (+2.74%) ▲|MRK147.96-1.92 (-1.28%) ▼|MS183.29-3.73 (-1.99%) ▼|MSFT523.97-8.98 (-1.69%) ▼|MU860.14-53.53 (-5.86%) ▼|NEE81.39+3.11 (+3.97%) ▲|NFLX67.22+2.18 (+3.35%) ▲|NKE38.27+0.74 (+1.96%) ▲|NOW156.69+3.57 (+2.33%) ▲|NVDA212.50-9.47 (-4.27%) ▼|ORCL123.41-5.72 (-4.43%) ▼|PEP138.27+3.57 (+2.65%) ▲|PFE30.25+0.40 (+1.34%) ▲|PG166.12+9.28 (+5.92%) ▲|PLTR197.07-4.65 (-2.31%) ▼|PM200.87+3.41 (+1.73%) ▲|QCOM172.75-5.22 (-2.93%) ▼|RTX192.53+0.93 (+0.49%) ▲|SBUX101.62+2.54 (+2.56%) ▲|SCHW92.21+0.57 (+0.62%) ▲|SO93.28+2.89 (+3.20%) ▲|SPG211.18+5.63 (+2.74%) ▲|T22.68+0.77 (+3.49%) ▲|TMO676.83-17.19 (-2.48%) ▼|TMUS158.27+4.52 (+2.94%) ▲|TSLA377.95-8.53 (-2.21%) ▼|TXN283.23-1.42 (-0.50%) ▼|UBER68.21+0.59 (+0.87%) ▲|UNH424.60+7.60 (+1.82%) ▲|UNP296.04+8.17 (+2.84%) ▲|UPS101.69+2.12 (+2.12%) ▲|USB59.91+0.86 (+1.45%) ▲|V413.95+6.10 (+1.50%) ▲|VZ44.80+1.24 (+2.84%) ▲|WFC83.02+0.60 (+0.73%) ▲|WMT120.45+2.65 (+2.25%) ▲|XOM177.34-0.75 (-0.42%) ▼|
19.5 C
New York
Thursday, October 22, 2026

Tag: medical

newsFORsourcecompanycontentinformation1releasesmarket

Trip.com Group Pioneers a Greener, More Inclusive Global Travel Ecosystem in 2024 Sustainability Report

Group launches new full-scale carbon emissions data feature across transport modesCountry Retreats Programme expands to more global destinations, driving rural developmentChampioning greater inclusion in...

ReproNovo Announces First Participant Included in U.S. Phase 2 Trial of RPN-001 for Male Infertility

LAUSANNE, Switzerland and COPENHAGEN, Denmark, July 01, 2025 (GLOBE NEWSWIRE) -- ReproNovo, a company dedicated to developing innovative treatments for reproductive medicine and women’s health, today announced that the first participant has been included in the company’s Phase 2 clinical trial of its lead candidate RPN-001 (leflutrozole), an orally administered aromatase inhibitor in development for the treatment of male infertility (https://clinicaltrials.gov/study/NCT06993155?term=Leflutrozole&rank=1).

DRC Medicine Ltd. Announces the Business Combination Agreement with Ribbon Acquisition Corp.

Combined Company Expected to be Listed on NASDAQ Global Market

Rakovina Therapeutics Announces Intention to Amend Debentures and Warrants

VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”) announces that it will apply to the TSX Venture Exchange (the “Exchange”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.

CentraLlVF Launches New Guaranteed Egg Donation Programs Through CEB and AWEB

Expanded blastocyst-guarantee programs now available through two CentraLlVF brands, supporting a wider range of Australian recipients LONDON, July 1, 2025 /PRNewswire/ -- CentraLlVF, a leading...

CentraLlVF Launches New Guaranteed Egg Donation Programs Through CEB and AWEB

Expanded blastocyst-guarantee programs now available through two CentraLlVF brands, supporting a wider range of Australian recipients LONDON, July 1, 2025 /PRNewswire/ -- CentraLlVF, a leading...

Susie White receives San Bernardino County Medical Society President’s Award

RANCHO CUCAMONGA, Calif., June 30, 2025 /PRNewswire/ -- Inland Empire Health Plan (IEHP) Chief Operating Officer Susie White received the San Bernardino County Medical...

Thought Leadership & Innovation Foundation Releases White Paper Showcasing Model for Non-Profit Collaboration to Improve Outcomes for Chronic Disease Communities

MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- The Thought Leadership & Innovation Foundation (TLI), a nonprofit at the forefront of health innovation, today announced the release of a groundbreaking white paper, A Model for Non-Profit Cooperation to Benefit Chronic Disease Communities. This report outlines TLI’s dynamic, multi-sectoral approach to supporting underserved patient populations through collaboration, data innovation, and stakeholder engagement.

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion...

The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are...

Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses. July 22, 2025 Deadline to file Lead Plaintiff Motion

Investors can contact the law firm at no cost to learn more about recovering their losses

TerrAscend Announces Strategic Exit from Michigan Market

Net Proceeds from divestitures to pay down Company debt

Australian digital health leaders come together to enable solutions for overlooked health challenges: Winners announced

Apps tackling nutritional literacy in migrant communities and child sleep issues to be developed, co-designed, tested and delivered to target populations as part of...

Powers Health forges Prime Vendor agreement with Medline

Northwest Indiana-based integrated health system to leverage Medline to drive product and process standardization NORTHFIELD, Ill., June 30, 2025 /PRNewswire/ -- Today, Medline announced it has entered into...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedical

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers